{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-023059","form_type":"8-K","ticker":"ORGO","cik":"0001661181","company_name":"Organogenesis Holdings Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.014611+00:00","generated_at":"2026-06-05T06:50:40.350364+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Organogenesis Q4 revenue $99.7M (-14% YoY); net loss $0.6M; FY2024 guides $445M-$470M","bullets":["Net revenue Q4 $99.7M (-14% YoY): Advanced Wound Care $93.2M (-14%), Surgical & Sports Medicine $6.5M (-3%).","Q4 net loss $0.6M vs net income $7.5M; adjusted net income $1.9M vs $8.9M.","FY2023 net income $4.9M vs $15.5M; adjusted EBITDA $42.6M vs $49.3M.","FY2024 revenue guidance $445M-$470M (3%-9% growth); net income (loss) range ($10.6M)-$4.6M.","Management highlights progress on ReNu program for knee osteoarthritis as key value driver."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-023059","json":"https://secwatch.observer/filing/0000950170-24-023059.json","markdown":"https://secwatch.observer/filing/0000950170-24-023059.md","text":"https://secwatch.observer/filing/0000950170-24-023059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661181/000095017024023059/0000950170-24-023059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661181/000095017024023059/orgo-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:50:40.350364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c3890c99c90947c4c23a0a294b576e486fa4418","claim":"Organogenesis Holdings Inc. reported the fourth quarter ended December 31, 2023 results: revenue $99.7 million, net income Net loss of $0.6 million.","evidence_excerpt":"Net revenue of $99.7 million for the fourth quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661181/000095017024023059/0000950170-24-023059-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$99.7 million"},{"label":"Net income","value":"Net loss of $0.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fe281c360ec9f4f86a964eb565b22681373ccc42","claim":"Organogenesis Holdings Inc. reported the fiscal year ended December 31, 2023 results: revenue $433.1 million, net income Net income of $4.9 million. Guidance initiated.","evidence_excerpt":"Net revenue of $433.1 million for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661181/000095017024023059/0000950170-24-023059-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$433.1 million"},{"label":"Net income","value":"Net income of $4.9 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}